|
COG NCTN Solid Malignancy Integrated Translational Science Center
|
5U10CA180884-05
|
$192,024
|
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Investigating mechanistic underpinnings and therapeutic potential of selective histone deacetylase and bromodomain inhibition for the treatment of non-small cell lung cancer
|
1K22CA222669-01
|
$182,485
|
|
ADEEGBE, OLAKUNLE
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Functional and Mechanistic Study of Histone Crotonylation in Hematological Malignancies
|
5R01CA204639-03
|
$698,696
|
|
ALLIS, CHARLES
|
ROCKEFELLER UNIVERSITY
|
|
Consolidated Basic Cancer Research Program
|
5P30CA010815-49
|
$2,645,581
|
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Role of Tim-3 in determining T cell immunity
|
5R01CA187975-04
|
$377,666
|
|
ANDERSON, ANA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Swedish childhood cancers study
|
Z01 CP010183-00550
|
$2,170
|
$434
|
Anderson, William
|
DCEG (NCI)
|
|
A clones genomic stability as biomarker of its DNA-damage resilience
|
5K99CA215256-02
|
$166,644
|
|
ANDOR, NOEMI
|
STANFORD UNIVERSITY
|
|
Clinical bacterial isolate engineered as an immunotherapy for prostate cancer
|
5F30CA203472-03
|
$49,524
|
|
ANKER, JONATHAN
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
Age and Diet: Major interacting factors that drive sporadic intestinal cancer
|
5R01CA174432-06
|
$660,173
|
|
AUGENLICHT, LEONARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Collaborative Human Tissue Network (CHTN)
|
5UM1CA183713-05
|
$841,585
|
|
AYERS, LEONA
|
OHIO STATE UNIVERSITY
|
|
Interferon Activated Necroptosis as a New Therapeutic Avenue for Kidney Cancer
|
5R01CA168621-05
|
$379,725
|
|
BALACHANDRAN, SIDDHARTH
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
Uncovering the role of individual RNA helicases in cancer through specific chemical inhibition
|
5F30CA203522-03
|
$49,524
|
|
BARKOVICH, KRISTER
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Washington University/ Siteman Cancer Center Lead Academic Site
|
5U10CA180833-05
|
$1,394,352
|
|
BARTLETT, NANCY
|
WASHINGTON UNIVERSITY
|
|
Cancer Pain: Nerve/Tumor Interactions
|
5R01CA084233-07
|
$335,452
|
$167,726
|
BEITZ, ALVIN
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
|
The role of AXL-ABL axis in Barretts carcinogenesis
|
5R01CA193219-04
|
$361,425
|
|
BELKHIRI, ABBES
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
Biochemical Analyses of Type II DNA Topoisomerases
|
5R01CA077373-21
|
$445,382
|
|
BERGER, JAMES
|
JOHNS HOPKINS UNIVERSITY
|
|
Epigenetic regulation by tumor suppressor p53
|
5R01CA078831-19
|
$352,848
|
|
BERGER, SHELLEY
|
UNIVERSITY OF PENNSYLVANIA
|
|
Antigen-specific T-cell Activation, Application to Vaccines for Cancer and AIDS
|
Z01 SC 004020
|
$1,350,223
|
$135,022
|
Berzofsky, Jay
|
CCR (NCI)
|
|
Delineating the mechanisms and clinical utility of mtDNA mutagenesis in cancer
|
5R01CA204894-02
|
$402,600
|
|
BIELAS, JASON
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
ITSC for Leukemia: Novel Molecular Strategies for NCTN: Individualized Therapie
|
5U10CA180861-05
|
$684,551
|
|
BLOOMFIELD, CLARA
|
OHIO STATE UNIVERSITY
|
|
Antitumor Antibiotics
|
5R01CA042056-35
|
$462,801
|
|
BOGER, DALE
|
SCRIPPS RESEARCH INSTITUTE
|
|
Chemical probes for specific targeting of matrix metallo proteases
|
5R01CA179253-05
|
$333,038
|
|
BOGYO, MATTHEW
|
STANFORD UNIVERSITY
|
|
Targeting GLI-dependent Transcription by GANT61 in Colon Cancer
|
5R01CA183921-04
|
$548,628
|
|
BOOHAKER, REBECCA
|
SOUTHERN RESEARCH INSTITUTE
|
|
Dissection of eIF4E dependent mRNA export
|
5R01CA080728-18
|
$210,799
|
|
BORDEN, KATHERINE
|
UNIVERSITY OF MONTREAL
|
|
Targeted proteomics to aid in the management of patients with stage IA lung adeno
|
1R21CA223335-01
|
$170,738
|
|
BORGIA, JEFFREY
|
RUSH UNIVERSITY MEDICAL CENTER
|
|
NCI NCTN-Network Lead Academic Site at UPCI
|
5U10CA180844-05
|
$898,424
|
|
BRUFSKY, ADAM
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care
|
5U10CA180867-05
|
$1,302,199
|
|
BURSTEIN, HAROLD
|
DANA-FARBER CANCER INST
|
|
Complex Role of HSF1 in Breast Cancer
|
5R01CA176326-05
|
$355,719
|
|
CALDERWOOD, STUART
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
The Ohio State University Comprehensive Cancer Center
|
3P30CA016058-33S1
|
$89,606
|
$76,866
|
CALIGIURI, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
Malignant melanoma studies using iPS derived melanocytes and Zebrafish
|
5F31CA196305-04
|
$28,524
|
|
CALLAHAN, SCOTT
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Functional imaging-directed adaptive therapy of head and neck cancer
|
5R01CA184153-04
|
$487,095
|
|
CAO, YUE
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Cachexia in ApcMin/+ mice: The role of IL-6
|
5R01CA121249-09
|
$243,653
|
|
CARSON, JAMES
|
UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA
|
|
Randomized Phase II Study of QS-DG +/- Trivalent Ganglioside Vaccine in Stage IV
|
1R21CA133866-01A1
|
$426,881
|
$140,871
|
Carvajal, Richard
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Genetic studies of homologous recombination deficiency in hispanic gastric cancer
|
1R01CA223978-01
|
$617,977
|
|
CARVAJAL CARMONA, LUIS
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
|
Effect of Aerobic Exercise on Genomic Signatures of Prostate Cancer Prognosis
|
5R01CA181802-05
|
$619,068
|
|
CHAN, JUNE
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Dietary sulfur, the gut microbiome, and colorectal cancer
|
5R01CA202704-03
|
$556,619
|
|
CHAN, ANDREW
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Intervention of Immune Tolerance by Small Molecules
|
5R01CA127483-11
|
$311,223
|
|
CHEN, SHU-HSIA
|
METHODIST HOSPITAL RESEARCH INSTITUTE
|
|
Mechanisms of p53 activation during stress response (MPI)
|
5R01CA141244-09
|
$376,591
|
|
CHEN, JIANDONG
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Signaling and Targeting of 6-Phosphogluconate Dehydrogenase in Human Cancers
|
5R01CA174786-05
|
$325,412
|
|
CHEN, JING
|
EMORY UNIVERSITY
|
|
Mitochondrial acetyl-CoA acetyltransferase 1 promotes the Warburg effect
|
5R01CA183594-05
|
$325,093
|
|
CHEN, JING
|
EMORY UNIVERSITY
|
|
Targeting key orphan nuclear receptor in lethal prostate cancer
|
5R01CA206222-03
|
$359,138
|
|
CHEN, HONGWU
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
|
CRAF-mediated vascular resistance to cancer therapies
|
5R01CA050286-29
|
$465,256
|
|
CHERESH, DAVID
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
|
Mechanistic Insights into ALK Fusion Biology Through Investigation of the Fusion Partner
|
5F31CA213744-02
|
$17,026
|
|
CHILDRESS, MERRIDA
|
VANDERBILT UNIVERSITY
|
|
Investigating the cytomegalovirus link to glioblastoma using a novel mouse model
|
5R01CA195532-04
|
$377,464
|
|
CHIOCCA, E
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Image-Guided Drug Delivery and Treatment for GIST
|
1R21CA223270-01
|
$219,893
|
|
CHOI, HAK SOO
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Improving treatment of cardiovascular risk factors in childhood cancer survivors
|
5R01CA204378-02
|
$734,545
|
|
CHOW, ERIC
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Prostate Cancer Bone Metastasis Biology and Targeting
|
5P01CA098912-14
|
$1,636,904
|
|
CHUNG, LELAND
|
CEDARS-SINAI MEDICAL CENTER
|
|
Prolyl isomerase function during Jak Stat signaling in breast cancer
|
5R01CA173305-05
|
$309,739
|
|
CLEVENGER, CHARLES
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
Translating Novel Antitumor Targets of Vitamin E into New Chemopreventive Agents
|
5R01CA172576-05
|
$319,550
|
|
CLINTON, STEVEN
|
OHIO STATE UNIVERSITY
|
|
Identifying and validating novel susceptibility genes for breast cancer
|
5R01CA176785-05
|
$684,391
|
|
COUCH, FERGUS
|
MAYO CLINIC ROCHESTER
|
Total relevant funding to Sarcoma, Bone (Sarcoma Subset) for this search: $10,883,018
|